Oncology News | pharmaphorum

News

Alkermes may separate oncology business, says CEO

Alkermes has said it is considering a spin-out of its cancer business into an independent, publicly-traded company, retaining its traditional focus on neurosciences.

News

BMS announces positive Reblozyl phase 3 results for MDS

Bristol Myers Squibb has announced positive topline results from its

News

Trial bias concern scuppers Y-mAbs brain cancer drug in FDA ...

Shares in US biotech Y-mAbs Therapeutics have lost almost a third of their value after FDA advisors unanimously rejected its brain cancer therapy 131I-omburtamab in 16 to 0 vote.

News

Radiology technician examens mammography test on location

After setbacks for Roche and Sanofi, AZ scores oral SERD win

AstraZeneca seems to have dodged the problems besetting other developers of oral selective oestrogen receptor degrader (SERD) drugs with a phase 2 win for its candidate camizestrant in a ph

News

Normunity de-stealths, launches Series A immune normalisers

Biotech start-up Normunity, Inc.

News

J&J nabs FDA okay for BCMA bispecific Tecvayli

Johnson & Johnson has secured another regulatory approval for its BCMAxCD3 bispecific antibody for multiple myeloma – Tecvayli – adding to the wide range of therapies available for the

Alkermes may separate oncology business, says CEO

BMS announces positive Reblozyl phase 3 results for MDS

Trial bias concern scuppers Y-mAbs brain cancer drug in FDA ...

After setbacks for Roche and Sanofi, AZ scores oral SERD win

Normunity de-stealths, launches Series A immune normalisers

J&J nabs FDA okay for BCMA bispecific Tecvayli

J&J abandons trial of atopic dermatitis drug

How to meet your physicians where they are online

News

Editor's Picks